<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03823378</url>
  </required_header>
  <id_info>
    <org_study_id>M16-763</org_study_id>
    <secondary_id>2018-002306-31</secondary_id>
    <nct_id>NCT03823378</nct_id>
  </id_info>
  <brief_title>A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Blind, Parallel Group Long Term Extension Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial With ABBV-105 Given Alone or in Combination With Upadacitinib (ABBV-599)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long-term extension (LTE) study to assess the safety, tolerability and efficacy of
      ABBV-105 and ABBV-599 in Rheumatoid Arthritis (RA) participants who have completed M16-063.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Anticipated">February 17, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either having a reasonable possibility or no reasonable possibility. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS) 28 (C-reactive protein (CRP)) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>DAS 28 is a validated index of rheumatoid arthritis disease activity. Scores on DAS 28 range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS Low Disease Activity (LDA)</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>LDA is defined as DAS 28 CRP &lt;= 3.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS Clinical Remission (CR)</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>CR is defined as DAS 28 CRP &lt; 2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Disease Activity Index (CDAI) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>CDAI is a validated measure of rheumatoid arthritis disease activity. Scores on CDAI range from 0 to 76 with a higher score meaning higher disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving LDA based on CDAI Criteria</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>LDA based on CDAI criteria defined as CDAI &lt;= 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving CR based on CDAI Criteria</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>CR based on CDAI criteria defined as CR &lt;= 2.8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 20 Response Rate</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 50 Response Rate</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology (ACR) 70 Response Rate</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>ACR criteria measure improvements in tender and swollen joint counts, patient assessments of pain, global disease activity and physical function, physician global assessment of disease activity and acute phase reactant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count (SJC) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>The change in SJC in participants who had peripheral arthritis will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tender Joint Count (TJC) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>The change in TJC in participants who had peripheral arthritis will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient's Assessment of Pain from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Patient's Assessment of Pain is assessed using visual analog scale (VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Assessment of Disease Activity (PtGA) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Patient Global Assessment of Disease Activity (PtGA) is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Global Assessment of Disease Activity (PhGA) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Physician Global Assessment of Disease Activity (PhGA) is assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire Disability Index (HAQ-DI) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>The HAQ-DI is a patient-reported questionnaire specific for RA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-Sensitivity C-Reactive Protein (hs-CRP) from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>hs-CRP was analyzed by a central laboratory. The median percent change from baseline in CRP is assessed at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Morning Stiffness from Baseline of Study M16-063</measure>
    <time_frame>Up to Week 60</time_frame>
    <description>Duration of morning stiffness on numeric rating scale (from 0 to 10) will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">97</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>Participants receiving Upadacitinib Dose A and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with upadacitinib dose A and placebo for ABBV-105</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving ABBV-105 dose C and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-105 dose C and placebo for upadacitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving ABBV-105 dose B and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-105 dose B and placebo for upadacitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving ABBV-105 dose A and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-105 dose A and placebo for upadacitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving ABBV-599</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered with ABBV-599 (ABBV-105 dose A and upadacitinib dose A)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Upadacitinib tablet will be administered orally.</description>
    <arm_group_label>Participants receiving ABBV-599</arm_group_label>
    <arm_group_label>Participants receiving Upadacitinib Dose A and placebo</arm_group_label>
    <other_name>ABT-494</other_name>
    <other_name>RINVOQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib placebo</intervention_name>
    <description>Upadacitinib placebo tablet will be administered orally.</description>
    <arm_group_label>Participants receiving ABBV-105 dose A and placebo</arm_group_label>
    <arm_group_label>Participants receiving ABBV-105 dose B and placebo</arm_group_label>
    <arm_group_label>Participants receiving ABBV-105 dose C and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-105 placebo</intervention_name>
    <description>ABBV-105 placebo tablet will be administered orally.</description>
    <arm_group_label>Participants receiving Upadacitinib Dose A and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-105</intervention_name>
    <description>ABBV-105 tablet will be administered orally.</description>
    <arm_group_label>Participants receiving ABBV-105 dose A and placebo</arm_group_label>
    <arm_group_label>Participants receiving ABBV-105 dose B and placebo</arm_group_label>
    <arm_group_label>Participants receiving ABBV-105 dose C and placebo</arm_group_label>
    <arm_group_label>Participants receiving ABBV-599</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant has completed M16-063.

          -  Participant has not developed any laboratory or clinical discontinuation criteria as
             defined in M16-063.

          -  Participant is willing and/or able to comply with procedures required in protocol.

        Exclusion Criteria:

          -  Participant is currently enrolled or planning to enroll in another interventional
             clinical study while participating in this study (except the preceding study M16-063).

          -  Participant requires vaccination with any live vaccine during study participation,
             including at least 30 days after the last dose of study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 207719</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 207722</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Assoc /ID# 207769</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 206852</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIADS Research Co Ltd /ID# 206853</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3N 0K6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hosp.-Toronto /ID# 206851</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik /ID# 213440</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatolog s.r.o. /ID# 209941</name>
      <address>
        <city>Jihlava 1</city>
        <state>Jihlava</state>
        <zip>586 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav Praha /ID# 209943</name>
      <address>
        <city>Prague 2</city>
        <state>Praha 2</state>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie MUDr. Klara Sirova /ID# 209944</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech a.s /ID# 209942</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 208186</name>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abauj-Zemplen</state>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház /ID# 208184</name>
      <address>
        <city>Nyíregyháza</city>
        <state>Szabolcs-Szatmar-Bereg</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo /ID# 208187</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C-MED/CMED Rehabilitációsközpont /ID# 208188</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center Orvosi-es Fogorvosi Kozpont /ID# 208185</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Kliniczne /ID# 209902</name>
      <address>
        <city>Cracow</city>
        <state>Malopolskie</state>
        <zip>30-149</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk Sc /Id# 212577</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <state>Mazowieckie</state>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NBR Polska /ID# 209904</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk, Nowak Sp.j. /ID# 212578</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatika - Centrum Reumatologii NZOZ /ID# 209903</name>
      <address>
        <city>Warsaw</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Un. Marques de Valdecilla /ID# 207729</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.U. Clinico San Carlos /ID# 207738</name>
      <address>
        <city>Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Malaga /ID# 207735</name>
      <address>
        <city>Málaga</city>
        <state>Malaga</state>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comple Hosp Univ de A Coruna /ID# 207732</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 207740</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Basurto /ID# 207737</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Nieves /ID# 209975</name>
      <address>
        <city>Granada</city>
        <zip>18013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe /ID# 207739</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oxford /ID# 210571</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>Related Info.</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ABBV-105</keyword>
  <keyword>Upadacitinib</keyword>
  <keyword>ABBV-599</keyword>
  <keyword>Rheumatoid Arthritis (RA)</keyword>
  <keyword>Long-term extension (LTE)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

